188 related articles for article (PubMed ID: 35613022)
21. Histone lysine-specific demethylase 1 (LSD1) protein is involved in Sal-like protein 4 (SALL4)-mediated transcriptional repression in hematopoietic stem cells.
Liu L; Souto J; Liao W; Jiang Y; Li Y; Nishinakamura R; Huang S; Rosengart T; Yang VW; Schuster M; Ma Y; Yang J
J Biol Chem; 2013 Nov; 288(48):34719-28. PubMed ID: 24163373
[TBL] [Abstract][Full Text] [Related]
22. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
Lee EJ; Zeidan AM
Expert Rev Hematol; 2015 Apr; 8(2):155-8. PubMed ID: 25697572
[TBL] [Abstract][Full Text] [Related]
23. Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome.
Grimm J; Binder M
Signal Transduct Target Ther; 2022 Aug; 7(1):276. PubMed ID: 35945228
[No Abstract] [Full Text] [Related]
24. Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia.
Szmigielska-Kapłon A; Robak T
Curr Cancer Drug Targets; 2011 Sep; 11(7):837-48. PubMed ID: 21762079
[TBL] [Abstract][Full Text] [Related]
25. Hypomethylating agent based combinations in higher risk myelodysplastic syndrome.
Chandhok NS; Lewis R; Prebet T
Leuk Lymphoma; 2020 May; 61(5):1012-1027. PubMed ID: 31814484
[TBL] [Abstract][Full Text] [Related]
26. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
[TBL] [Abstract][Full Text] [Related]
27. Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide.
Liu BH; Jobichen C; Chia CSB; Chan THM; Tang JP; Chung TXY; Li J; Poulsen A; Hung AW; Koh-Stenta X; Tan YS; Verma CS; Tan HK; Wu CS; Li F; Hill J; Joy J; Yang H; Chai L; Sivaraman J; Tenen DG
Proc Natl Acad Sci U S A; 2018 Jul; 115(30):E7119-E7128. PubMed ID: 29976840
[TBL] [Abstract][Full Text] [Related]
28. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Taylor J; Mi X; Penson AV; Paffenholz SV; Alvarez K; Sigler A; Chung SS; Rampal RK; Park JH; Stein EM; Tallman MS; Sen F; Gönen M; Abdel-Wahab O; Klimek VM
Lancet Haematol; 2020 Aug; 7(8):e566-e574. PubMed ID: 32735836
[TBL] [Abstract][Full Text] [Related]
29. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
30. Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure.
Patel SS; Sekeres MA; Nazha A
Leuk Lymphoma; 2017 Nov; 58(11):2532-2539. PubMed ID: 28351181
[TBL] [Abstract][Full Text] [Related]
31. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
Sekeres MA
Leuk Lymphoma; 2015; 56(12):3267-9. PubMed ID: 26077360
[TBL] [Abstract][Full Text] [Related]
32. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
[TBL] [Abstract][Full Text] [Related]
33. SALL4: An Intriguing Therapeutic Target in Cancer Treatment.
Moein S; Tenen DG; Amabile G; Chai L
Cells; 2022 Aug; 11(16):. PubMed ID: 36010677
[TBL] [Abstract][Full Text] [Related]
34. Stem cell gene SALL4 suppresses transcription through recruitment of DNA methyltransferases.
Yang J; Corsello TR; Ma Y
J Biol Chem; 2012 Jan; 287(3):1996-2005. PubMed ID: 22128185
[TBL] [Abstract][Full Text] [Related]
35. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Kadia TM; Jabbour E; Kantarjian H
Semin Oncol; 2011 Oct; 38(5):682-92. PubMed ID: 21943675
[TBL] [Abstract][Full Text] [Related]
36. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
[TBL] [Abstract][Full Text] [Related]
37. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
[TBL] [Abstract][Full Text] [Related]
38. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.
Santini V; Melnick A; Maciejewski JP; Duprez E; Nervi C; Cocco L; Ford KG; Mufti G
Crit Rev Oncol Hematol; 2013 Nov; 88(2):231-45. PubMed ID: 23838480
[TBL] [Abstract][Full Text] [Related]
39. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
40. Life after hypomethylating agents in myelodysplastic syndrome: new strategies.
Santini V
Curr Opin Hematol; 2015 Mar; 22(2):155-62. PubMed ID: 25603477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
